IMT is responsible for the design and fabrication of ALDESORTER and the disposable MEMS sorting chips. Aldagen has strong expertise in the field of cell therapy, and one of the top clinical development portfolio in regenerative medicine. Aldagen is responsible for the labeling of cells and chemistry for conducting clinical trials with the ALDESORTER and commercialization of ALDESORTER system. John Foster, CEO of IMT, said: ‘It has always been IMT aims to cellular therapies for the treatment of some of the most insidious human diseases we provide particularly look forward with Aldagen whose ALDESORT used product , the partnership in clinical trials. Today. We expect that the combination of Aldagen and IMT – cell therapies are work, fab very real and positive difference in the lives of people produce.

OccasionAldagen has running currently has three clinical trials stem and progenitor stem and progenitor cell cell populations with his ALDESORT product Current clinical trials are evaluating the use of the populations in the treatment of ischemic heart failure, critical limb ischemia and pediatric. Cancer and genetic disorders. Currently, there are 100,000 s of patients in the United States who suffer from these conditions with few viable treatment options. Also believes Aldagen these cell populations could neuronal neural conditions and orthopedic conditions to treat.Research Philippe Autier the European Institute of Oncology in Milan proposes melanoma may be at least a two step process, with various types of sunlight Last Mole in the childhood and its growth causes to greater Mole to be later malignant.

Sunscreens as the means as a means to protect sun, but they can has the opposite effect of, submitted a report in the magazine the the National Cancer Institute.